Research Disclaimer
This is a research documentation site, not a medical advice platform.
Scope of Content
All content on STIM.bio describes a research framework for investigating biological resilience mechanisms. It does not constitute:
- Medical advice or diagnosis
- Treatment recommendations for specific conditions
- FDA-approved therapeutic claims
- Substitute for professional clinical consultation
Investigational Compounds
The following substances are discussed in the context of understory and translational research:
| Compound / Class | Research Context | Regulatory Status |
|---|---|---|
| Laxogenin (5α-hydroxy-laxogenin) | Proteostasis / chemical chaperone | Investigational; not FDA-approved |
| Astilbin | STIM1/Orai1 inhibition; Th17/Treg modulation | Investigational; not FDA-approved |
| Smilax glabra extract | Traditional use; phytochemical analysis | Dietary supplement (varies by jurisdiction) |
| Tauroursodeoxycholic acid (TUDCA) | ER stress / chemical chaperone | Prescription (US); supplement (EU) |
Evidence Level
Research cited on this site ranges from:
- Peer-reviewed primary literature (in vitro, animal models)
- Ethnobotanical and pharmacological reviews
- Mechanistic hypotheses derived from cross-kingdom analogy (xenohormesis)
Human clinical trials specifically validating the STIM protocol for MCAS, Morbihan disease, or FPIES do not yet exist.
Reader Responsibility
If you are a patient or lay reader: do not use this site to self-prescribe. If you are a researcher: verify all claims against primary sources before relying on summaries.
Last updated: 2026-05-16 | Framework version: STIM v7.0011